Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?

Southern Med Review

article

Zulzaga, Zuzaan¹  Myagmarsuren, Erdenetuya²  Woerdenbag, Herman J.⁴  van Puijenbroek, Eugene P.⁵ 

[1] Association of Mongolian Pharmacy Professionals;Department of Clinical Pharmacy and Management, School of Pharmacy, Mongolian National University of Medical Sciences;Department of Pharmacy, Mongolian Japan Hospital of Mongolian National University of Medical Sciences;Department of Pharmaceutical Technology and Biopharmacy, University of Groningen;Pharmacovigilance Centre Lareb;Department of PharmacoTherapy, University of Groningen

关键词: Adverse drug reaction;    Mongolia;    Medicines safety;   

DOI  :  10.1186/s40545-021-00298-8

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the features of the Mongolian health care and pharmaceutical systems, as well as the current development of the adverse drug reaction reporting system.

【 授权许可】

Unknown